![Hoe eenvoudige semantiek onze AI-citaties met 642% verhoogde [Nieuwe resultaten]](https://www.pharmamarketeer.nl/wp-content/uploads/2026/01/719-370x300.jpg)
Inbrija (levodopa inhalation powder; Acorda Therapeutics) is the first and only FDA-approved inhaled levodopa for intermittent treatment of OFF episodes in patients with Parkinson’s disease taking...
Als marketeers het niet doen, wie dan wél?
Het meest verontrustende aspect van de onlangs geïntroduceerde gelehesjesbeweging, is misschien wel de enorme volkswoede die de lont in het kruitvat bleek: de verhoging van de dieselprijzen in Frankrijk. Vrees van mij...
AstraZeneca receives European approval for Bevespi Aerosphere to treat COPD
AstraZeneca announced that the European Commission (EC) has approved Bevespi Aerosphere (glycopyrronium/formoterol fumarate) in a pressurised metered-dose inhaler (pMDI) as a maintenance dual bronchodilator treatment to...
Ethiek in marketing, een noodzaak of kans?
Hoe goed gaan marketing en consumentenwelzijn samen? Marketing creëert een vraag door in te spelen op behoeften en stimuleert zo sterk mogelijk het gewenste gedrag van de klant. Ligt gebruik en misbruik van...
US FDA approves Lynparza for first-line maintenance therapy in BRCA-mutated advanced ovarian cancer
AstraZeneca and Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Lynparza for use as maintenance treatment of adult patients with...
New bacteria-based drug delivery system could radically expand cancer treatment options
An interdisciplinary team of three Virginia Tech faculty members affiliated with the Macromolecules Innovation Institute has created a drug delivery system that could radically expand cancer treatment options.
Bruins: risico’s voor levering medicijnen bij no-deal-brexit
Minister Bruins waarschuwt de gezondheidszorg in Nederland voor de mogelijke gevolgen van een no-deal-brexit. Als er 29 maart geen akkoord tussen de Europese Unie en het Verenigde Koninkrijk is over de brexit, bestaat...
Chugai gains FDA breakthrough status for rare CNS treatment
The FDA has granted Breakthrough Therapy Designation to Chugai’s satralizumab, a treatment currently in phase 3 for the rare CNS disorders neuromyelitis optica and neuromyelitis optica spectrum disorders (NMO/NMOSD).
Amsterdam maakt zich klaar voor het zwaarbevochten medicijnagentschap
Getooid in een oranje hesje en met een gele bouwhelm op zegt minister Bruno Bruins het nog maar eens: hij is ‘dolblij’ dat het Europees Geneesmiddelenagentschap (EMA) straks van Londen naar Amsterdam...
Teva reports positive results from phase IIIb FOCUS study of fremanezumab in adults with migraine
Teva Pharmaceutical Industries Ltd announced positive topline results from the phase IIIb FOCUS study that evaluated the efficacy and safety of fremanezumab for the preventive treatment of migraine in adult patients who...
YoastCon 2019: Dé SEO & online marketing conferentie die je niet wilt missen!
Wil je alles weten over SEO & online marketing in 2019? Ga naar YoastCon op 7 en 8 februari in Nijmegen! Laat je inspireren en bijpraten door internationale experts uit diverse vakgebieden.
Lilly, Aduro Biotech enter research collaboration to develop novel immunotherapies
Eli Lilly and Company and Aduro Biotech, Inc. announced a research collaboration and exclusive license agreement for Aduro’s cGAS─STING Pathway Inhibitor program for the research and development of novel
Motegrity Approved for Chronic Idiopathic Constipation in Adults
Shire announced that the Food and Drug Administration (FDA) has approved Motegrity (prucalopride) tablets for the treatment of adults with chronic idiopathic constipation (CIC).
Oxtellar XR Gains Monotherapy Indication for Partial-Onset Seizures
Supernus announced that the FDA has approved the supplemental New Drug Application for Oxtellar XR (oxcarbazepine) to include monotherapy use for the treatment of partial-onset seizures patients aged ≥6 years.
Grote Content Marketing Onderzoek 2018 van start
De tweede editie van het Grote Content Marketing Onderzoek is van start gegaan. Deze editie, geïnitieerd door Platform Content, is uitgebreid met vragen over de branding van contentmarketing, het niveau van de benodigde...
Celltrion and Teva’s Herceptin biosimilar secures FDA approval in breast cancer
Israeli and South Korean-based drug makers Teva and Celltrion are set to move in on the market share occupied by Roche and Genentech’s Herceptin (trastuzumab) with the announcement that their own biosimilar version of...
EMA’s committee recommends seven medicines for approval at its December 10─13, 2018 meeting
The EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended seven medicines for approval at its December 10─13, 2018 meeting.
Pharma in 2018: Looking back, looking forward
2018 has been a year characterised by uncertainty, but also significant leaps in research, access, and industry deals. With 2019 bringing a host of new challenges, not least of which is Brexit, Pharmafocus spoke to...
